MEDICINA NUCLEARE - Crosetto Foundation
MEDICINA NUCLEARE - Crosetto Foundation
MEDICINA NUCLEARE - Crosetto Foundation
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
60. Demetri, G.D. et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl.<br />
J. Med. 347, 472–480<br />
61. Holdsworth, C.H. et al. (2007) CT and PET: early prognostic indicators of response to imatinib mesylate in patients with<br />
gastrointestinal stromal tumor. Am. J. Roentgenol. 189, W324–W330<br />
62. Grimpen, F. et al. (2005) Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in<br />
gastrointestinal stromal tumour. Lancet Oncol. 6, 724–727<br />
63. Su, H. et al. (2006) Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment<br />
response to epidermal growth factor receptor kinase inhibitors. Clin. Cancer Res. 12, 5659–5667<br />
64. Smith-Jones, P.M. et al. (2006) Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET.<br />
J. Nucl. Med. 47, 793–796<br />
65. Dimitrakopoulou-Strauss, A. et al. (2007) A recent application of fluoro-18-deoxyglucose positron emission tomography,<br />
treatment monitoring with a mammalian target of rapamycin inhibitor: an example of a patient with a desmoplastic small<br />
round cell tumor. Hell. J. Nucl. Med. 10, 77–79<br />
66. Smith-Jones, P.M. et al. (2004) Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat.<br />
Biotechnol. 22, 701–706<br />
67. Cohen, R.M. et al. (2003) Higher in vivo muscarinic-2 receptor distribution volumes in aging subjects with an<br />
apolipoprotein E-epsilon4 allele. Synapse 49, 150–156<br />
68. Balaban, E. (1998) Eugenics and individual phenotypic variation: to what extent is biology a predictive science? Science<br />
11, 331–356<br />
69. Cantor, C.R. (2005) The use of genetic SNPs as new diagnostic markers in preventive medicine. Ann. N. Y. Acad. Sci.<br />
1055, 48–57<br />
70. El-Deiry, W.S. et al. (2006) Imaging and oncologic drug development. J. Clin. Oncol. 4, 3261–3273<br />
71. Ng, J.H. and Ilag, L.L. (2004) Streamlining drug development: finding the right drug against the right target to treat the<br />
right disease. Drug Discov. Today 9, 59.<br />
_<br />
AIMN - Notiziario elettronico di Medicina Nucleare ed Imaging Molecolare, Anno V, n 2, 2009 pag. 25/85
Change language